Villejuif

• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
• A Phase 1 Study of IM-1021 in Participants with Advanced Cancer Recruiting
  2025-523160-20-00 1 2026-03-23 Advanced solid tumors
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• A clinical study of MK-3120 in people with bladder cancer (MK-3120-003) Recruiting
  2025-520467-40-00 9 2026-03-16 High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• Visugromab, nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post a … Recruiting
  2025-520675-86-00 4 2026-03-10 Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Li
• A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants … Recruiting
  2024-519622-20-00 1 2026-02-27 Advanced Solid Tumors Harboring RAS Mutation(S)
• A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms. Recruiting
  2024-520353-21-00 3 2026-02-24 Myeloproliferative Neoplasms
• A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) Recruiting
  2025-522398-12-00 3 2026-01-30 Locally advanced or metastatic NSCLC
• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• A Phase 1/2 First-Time-in-Human study of GSK5458514 administered alone or in combination with other anti-cancer agents in participants with … Recruiting
  2025-521581-10-00 7 2026-01-16 Neoplasms, Prostate
• A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01] Recruiting
  2022-501607-27-00 7 2026-01-06 Relapsed or refractory B-cell Non-Hodgkin lymphoma
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be … Recruiting
  2024-510778-26-00 4 2025-12-19 Metastatic Non-Small-Cell Lung Cancer
• A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non-muscle invasive bladder cancer ma … Recruiting
  2024-512029-10-00 5 2025-12-05 Intermediate risk, non-muscle invasive bladder cancer
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting
  2025-521040-37-00 5 2025-11-26 HER2-positive early breast cancer
• AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors Recruiting
  2025-521707-48-00 1 2025-11-26 KRAS Altered Advanced or Metastatic Solid Tumors
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
• An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec … Recruiting
  2025-520582-51-00 5 2025-10-17 Hormone receptor positive breast cancer
• An Early Phase Clinical Trial to Evaluate COM701 in Relapsed Platinum Sensitive Ovarian Cancer (PSOC) Recruiting
  2025-521125-33-00 9 2025-09-05 Ovarian Cancer
• A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult P … Recruiting
  2023-505479-56-00 1 2025-07-30 Follicular lymphoma (FL)
• A Phase 1, Open-Label Dose Escalation and Expansion study of SNV1521 in Participants with Advanced Solid Tumors Recruiting
  2025-520557-36-00 1 2025-07-24 Advanced Solid Tumors
• A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms Recruiting
  2023-506348-17-00 4 2025-07-22 Relapsed/refractory (r/r) mature B cell neoplasms who have relapsed af

Showing 73–96 of 961 trials